Nemaura Medical Inc. Stock

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 03:19:01 2024-04-23 pm EDT 5-day change 1st Jan Change
0.06 USD -16.67% Intraday chart for Nemaura Medical Inc. -19.03% -72.60%
Sales 2024 * 200K Sales 2025 * 1.4M Capitalization 2.42M
Net income 2024 * -9M Net income 2025 * -12M EV / Sales 2024 * 12.1 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.73 x
P/E ratio 2024 *
-0.19 x
P/E ratio 2025 *
-0.14 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day-16.67%
1 week-19.03%
Current month-32.58%
1 month-29.25%
3 months-37.82%
6 months-77.01%
Current year-72.60%
More quotes
1 week
0.06
Extreme 0.06
0.09
1 month
0.06
Extreme 0.06
0.10
Current year
0.06
Extreme 0.06
0.21
1 year
0.06
Extreme 0.06
1.25
3 years
0.06
Extreme 0.06
17.40
5 years
0.06
Extreme 0.06
17.40
10 years
0.06
Extreme 0.06
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Chief Executive Officer 50 13-12-23
More insiders
Date Price Change Volume
24-04-23 0.06 -16.67% 119,656
24-04-22 0.072 -14.34% 42,662
24-04-19 0.084 +5.33% 11,913
24-04-18 0.0798 +5.00% 27,920
24-04-17 0.076 +2.56% 29,402

Delayed Quote OTC Markets, April 23, 2024 at 03:19 pm EDT

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.06 USD
Average target price
1.5 USD
Spread / Average Target
+2,400.00%
Consensus